ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Apoptosis >Bcl-2 inhibitors >ABT-199

ABT-199

ABT-199 Suppliers list
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +86 21 5161 9050/ 5187 7795
Email: ivan@atkchemical.com
Products Intro: Product Name:ABT-199
CAS:1257044-40-8
Purity:0.99 Package:5MG;10MG;50MG;100MG,1G,5G
Company Name: Beijing Yibai Biotechnology Co., Ltd
Tel: 0086-182-6772-3597
Email: sales04@yibaibiotech.com
Products Intro: Product Name:Venetoclax/ABT-199
CAS:1257044-40-8
Purity:99%+ Package:1ASSAYS;0USD|10g;0USD|50g;0USD|100g;0USD|1KG;0USD
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Email: info@dakenchem.com
Products Intro: Product Name:ABT-199
CAS:1257044-40-8
Purity:99% Package:100g,500g,1KG,10KG,100KG
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd
Tel: 010-60279497
Email: sales01@cooperate-pharm.com
Products Intro: Product Name:ABT-199
CAS:1257044-40-8
Purity:99% Package:1G;50USD
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: CAS:1257044-40-8
Purity:99% Package:500G;1KG;5KG;25KG

Lastest Price from ABT-199 manufacturers

  • Venetoclax/ABT-199
  • US $0.00-0.00 / KG
  • 2020-07-22
  • CAS:1257044-40-8
  • Min. Order: 1g
  • Purity: 99%+
  • Supply Ability: 25KG/month
  • Tetracycline
  • US $1.00 / Kg/Drum
  • 2019-10-29
  • CAS:1257044-40-8
  • Min. Order: 25Kg/Drum
  • Purity: 99%
  • Supply Ability: 1ton
  • ABT-199
  • US $1.00 / kg
  • 2019-07-06
  • CAS:1257044-40-8
  • Min. Order: 1kg
  • Purity: 95%-99%
  • Supply Ability: 100kg

Related articles

  • What is Venetoclax/ABT-199?
  • Venetoclax is a first-in-class, oral, selective BCL-2 inhibitor (BH3-only mimetic). The drug is approved in numerous countries....
  • Feb 10,2020
ABT-199 Basic information
Description BCL-2 inhibitor Mechanism of action Cytotoxic Activity References
Product Name:ABT-199
Synonyms:ABT-199;ABT-199 (GDC-0199);GDC-0199;ABT-199 100MG;2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)met;ABT-199, Venetoclax;ABT-199 (GDC-0199)Venetoclax;4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]ami;Venclexta
CAS:1257044-40-8
MF:C45H50ClN7O7S
MW:868.4392
EINECS:820-130-9
Product Categories:API;Inhibitors;Apis;Inhibitor
Mol File:1257044-40-8.mol
ABT-199 Structure
ABT-199 Chemical Properties
density 1.340±0.06 g/cm3(Predicted)
form Yellow solid.
pka4.09±0.10(Predicted)
Safety Information
MSDS Information
ABT-199 Usage And Synthesis
DescriptionABT-199, also known as venetoclax, is a small, oral chemical molecule used for the treatment of chronic lymphocytic leukemia (CLL) associated with a specific chromosomal abnormality. As a second line treatment drug of CLL, ABT-199 take effects through acting as a BH3-mimetic and inhibitor of Bcl-2 (the anti-apoptotic B-cell lymphoma-2protein), further inducing apoptosis of CLL cells but not platelets. It also has the potential for the treatment of ER-positive breast cancer.
BCL-2 inhibitor

Venetoclax is a first-in-class, oral, selective BCL-2 inhibitor (BH3-only mimetic). The drug is approved in numerous countries, including those of the EU and in the USA, for the treatment of adults with relapsed or refractory (RR) CLL. The drug arose from research by Abbott Laboratories (now AbbVie) during a collaboration with Genentech and is being codeveloped by AbbVie and Genentech/Roche primarily.

Mechanism of action

Venetoclax has high affinity for BCL-2, binding to the protein with an affinity more than three orders of magnitude greater than to BCL-XL or BCL-W in vitro. By binding to BCL-2, the drug displaces BCL-2-bound proapoptotic proteins (such as BIM), resulting in the permeabilization of mitochondrial outer membranes, activation of caspases, and restoration of cancer cell apoptosis, with this process requiring the apoptosis regulators BAX or BAK.

Cytotoxic Activity

Venetoclax displayed cytotoxic activity in various tumour samples/cell lines, including some derived from CLLs, various other NHL subtypes, acute lymphoblastic leukaemias (ALLs), AMLs, chronic myeloid leukaemias (CMLs) and MMs. Notably, the sensitivity of venetoclax correlated with higher BCL-2 expression, with a BCL-2 high status [i.e. BCL-2 gains, BCL-2 amplifications, or the t translocation, which is a notable cause of deregulated BCL-2 expression] and higher BCL-2/MCL-1 ratios being potentially predictive of sensitivity to the drug.

Referenceshttps://en.wikipedia.org/wiki/Venetoclax
Vogler, M, et al. "ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets." British Journal of Haematology 163.1(2013):139-42.
Vaillant, François, et al. "Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer." Cancer Cell 24.1(2013):120-9.
Lindeman, G. J., et al. "Abstract P2-09-01: Targeting BCL-2 with the BH3 mimetic ABT-199 in ER-positive breast cancer." Cancer Research 73.24 Supplement (2013):P2-09-01-P2-09-01.
DefinitionChEBI: A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.
ABT-199 Preparation Products And Raw materials
Tag:ABT-199(1257044-40-8) Related Product Information
2-[(1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy]-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl]methyl]piperazin-1-yl]benzoic acid 1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazine 1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]- Methyl 4-Fluoro-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzoate 3-nitro-4-((tetrahydro-2H-pyran-4-yl)MethylaMino)benzenesulfonaMide 4'-chloro-5,5-diMethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carbaldehyde Vipadenant 2-(3-fluorophenyl)-3-methylmorpholine(3-fluorophenmetrazine)(3-FPM) Osimertinib mesylate ADB-FUBINACA 4-Ethylmethcathinone THJ-018 Bortezomib ABT 737 Trametinib ABT 263 Ibrutinib Olaparib